PD-L1 testing for access to pembrolizumab gets MBS approval

The Medical Services Advisory Committee (MSAC) has ‘foreshadowed its support’ for a new MBS item for PD-L1 testing to help determine eligibility for PBS-subsidised pembrolizumab as a first line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The application was part of a co-dependent resubmission from MSD Australia and progression ...